AgentFlareMarkets · Health Care · LLY · NYSE
Eli Lilly (LLY) at $1,282.03, Just Above Its Six-Month High of $1,280.34
Eli Lilly shares last traded at $1,282.03, with a market cap of $1.21T, just above a six-month high of $1,280.34. Recent court and earnings-related headlines are drawing attention.
You're reading the full report — free for humans and search engines.
The same content ships as a structured JSON dataset (normalized facts, sources and
citation arrays, no HTML parsing) so AI agents can consume it directly — metered per fetch via the open
HTTP 402 payment protocol.
crawlerAutoPrice=true · verify at https://esa.aisa.one/api/v1/access/verify
Price action and valuation versus peers
Shares last traded at $1,282.03, up 0.23% on the day. Over roughly one month the stock is down 6.0%, while over about three months it is up 3.6% and over about six months it is up 32.7%. The six-month high of $1,280.34 was set on 2026-08-19, and the six-month low of $851.21 came on 2026-04-29. Valuation metrics include a P/E of 42.89, P/S of 15.15, P/B of 35.62, EV/EBITDA of 35.06 and PEG of 0.45. Against tracked peers UNH and JNJ, the median P/E is 40.88.
What recent headlines say
Several outlets reported on 2026-10-26 and 2026-10-27 that a US judge declined to block Eli Lilly's weight-loss drug advertising, ruling against Novo Nordisk. Bloomberg.com reported that Novo Nordisk lost the US ruling over the Lilly obesity drug ads, while Investing.com carried a Reuters report that the judge refused to block the ads. Indianapolis Business Journal said the judge won't block Lilly ads for weight-loss drugs. Separately, Kalkine reported that Eli Lilly extended clinical evidence as medicine sales support higher guidance, and TradingView previewed Q3 earnings for drug and biotech stocks.
Fundamentals
| Market cap | $1.21T | Enterprise value | $1.25T |
| P/E | 42.89 | P/S | 15.15 |
| P/B | 35.62 | EV/EBITDA | 35.06 |
| PEG | 0.45 | EPS | $29.89 |
| Debt/equity | 1.62 | Current ratio | 1.35 |
| FCF yield | 1.5% | Payout ratio | 21.7% |
Recent headlines
- What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView TradingView · 2026-10-27
- Judge denied Novo Nordisk bid to block Eli Lilly weight-loss drug ads - Quartz Quartz · 2026-10-27
- Eli Lilly and Company (NYSE:LLY) Extends Clinical Evidence as Medicine Sales Support Higher Guidance - Kalkine Kalkine · 2026-10-27
- Judge won’t block Lilly ads for weight-loss drugs in ruling against Novo Nordisk - Indianapolis Business Journal Indianapolis Business Journal · 2026-10-27
- US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk By Reuters - Investing.com Investing.com · 2026-10-26
- Novo Nordisk Loses US Ruling Over Eli Lilly Obesity Drug Ads - Bloomberg.com Bloomberg.com · 2026-10-26
In the AgentFlare Newswire
- Big Tech earnings wave collides with a Fed meeting 2026-10-27 · earnings
- Coca-Cola, Boeing and Eli Lilly also report in a crowded week 2026-10-26 · earnings
- Goldman Sachs resets Eli Lilly price target ahead of earnings 2026-10-25 · earnings
- Big Tech earnings and a Fed meeting crowd the week ahead 2026-10-25 · markets
- Lilly reports 79.3% response rate for ovarian cancer drug Sofe-M 2026-10-25 · markets
- Eli Lilly climbs about 4.0% on obesity and diabetes data 2026-10-15 · markets
What to watch
- Q3 earnings for drug and biotech stocks, as previewed by TradingView
- Novo Nordisk's bid to block Eli Lilly weight-loss drug ads following the US ruling
FAQ
How does Eli Lilly's P/E compare with its peers?
Eli Lilly's P/E is 42.89, compared with a tracked Health Care peer median P/E of 40.88 across UNH and JNJ.
What did the court ruling involving Novo Nordisk concern?
Reports from Bloomberg.com, Investing.com and Indianapolis Business Journal said a US judge refused to block Eli Lilly's weight-loss drug ads, ruling against Novo Nordisk.
How this page is made. Prices, fundamentals and headlines come from the AISA Financial API; peers are the other tracked stocks in the same sector. The profile is written by a language model from those numbers and headlines only — figures not in the data are removed. Nothing here is investment advice.
Sources & citations
- What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings? - TradingView TradingView · 2026-10-27
- Judge denied Novo Nordisk bid to block Eli Lilly weight-loss drug ads - Quartz Quartz · 2026-10-27
- Eli Lilly and Company (NYSE:LLY) Extends Clinical Evidence as Medicine Sales Support Higher Guidance - Kalkine Kalkine · 2026-10-27
- Judge won’t block Lilly ads for weight-loss drugs in ruling against Novo Nordisk - Indianapolis Business Journal Indianapolis Business Journal · 2026-10-27
- US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk By Reuters - Investing.com Investing.com · 2026-10-26
- AISA Financial API
- Eli Lilly & Co SEC filings